CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Sauflon Pharmaceuticals

Sauflon Pharmaceuticals is a Hicksville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medexus

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

Regulatory Affairs Professionals Society

RAPS is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.

Novocol Pharmaceutical

Novocol Pharmaceutical is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kalypsys

Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.